SCHEMBL23218192

SCHEMBL23218192

Cc1cc2occ(CO)c2cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.49
ALOX15 P16050 2/20 0.49
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
MAOB P27338 1/20 0.38
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 2/20 0.36
TSHR P16473 1/20 0.36
MTNR1A P48039 1/20 0.36
RAB9A P51151 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HPGD P15428 1/20 0.36
NPC1 O15118 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
SIRT1 Q96EB6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853102 1.00 PTPN1 (0.49) PTPN1ALOX15MAPTSMN1; SMN2TP53
SCHEMBL30436701 0.81 ALOX15 (0.50) ALOX15MAPTSMN1; SMN2MAOBKMT2A
SCHEMBL19956965 0.77 PTPN1 (0.57) PTPN1ALOX15ALDH1A1TSHRHPGD
SCHEMBL28803988 0.76 MAOB (0.38) ALOX15MAPTSMN1; SMN2MAOB
SCHEMBL177538 0.71 MAOB (0.47) PTPN1MAPTTP53MAOBALDH1A1
SCHEMBL19627181 0.71 ALOX15 (0.60) ALOX15MAPTSMN1; SMN2KMT2AALDH1A1
SCHEMBL13696620 0.71 CD44 (0.42) ALOX15SMN1; SMN2ALDH1A1NPSR1
SCHEMBL23218759 0.69 MAOB (0.50) PTPN1ALOX15MAPTMAOBKMT2A
SCHEMBL15898905 0.69 AHR (0.39) PTPN1ALOX15MAPTSMN1; SMN2TP53
SCHEMBL13696619 0.69 SHBG (0.42) ALOX15SMN1; SMN2ALDH1A1NPSR1SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 PTPN1 3833/4885ALOX15 3407/4885MAPT 234/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PTPN1 3533/4885ALOX15 224/4885MAPT 4793/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTPN1 3369/4885ALOX15 276/4885MAPT 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.